Switching Patterns Among Neovascular Age-Related Macular Degeneration: Genentech’s Vabysmo Rising, Regeneron’s Eylea and Genentech’s Off-Label Avastin Remain Strong, According to Spherix Global Insights
Despite the availability of new agents, established brands remain market leaders within the switch segment. EXTON, Pa., January 18, 2023/PR Newswire/ The switch landscape represents an active segment of the market where brands have the opportunity to capture share. Spherix’s RealWorld Dynamix™ service takes a unique approach to the typical collection of patient-level data, capturing […]
Implications of Biosimilar Availability in the United States’ Ophthalmology Markets Highlighted in New Spherix Global Insights Study
80 US ophthalmologists provided feedback on their use and perceptions of biosimilar agents and their impact on the total treatment landscape EXTON, Pa., January 10, 2023 – Ophthalmologists saw the entry of the first biosimilars into the armamentarium in 2022 with the launch of Biogen and Samsung’s Byooviz and Coherus Bioscience’s Cimerli (both biosimilars to […]
Ophthalmologists Report Need for Education and Cooperation Between Treating Physicians and Referrers for Geographic Atrophy, According to Spherix Global Insights
A high percentage of GA patients are either being seen for the first time, or not returning for follow-up visits due to lack of options according to non-treating clinicians, making the need for timely referrals essential for getting new treatments to patients. With Apellis’ pegcetacoplan nearing the finish line and Iveric Bios’ avacincaptad pegol not […]
The Importance of Advocacy and Community Allyship
The World Health Organization (WHO) estimates that at least 2.2 billion people globally have a near or distance vision impairment. In at least 1 billion – or almost half – of these cases, vision impairment could have been prevented or has yet to be addressed.1 The majority of people with vision impairment and blindness are […]
Off-Label Avastin (Genentech) Dominates First-Line Biologic Use in Diabetic Retinopathy Despite Eylea’s (Regeneron) Best Efforts to Secure Share in the Space, According to Spherix Global Insights
While Eylea holds the second-place position, newcomer Vabysmo (Genentech) has already captured a small piece of the market and is the anticipated first switch for many current Eylea patients EXTON, Pa., November 3, 2022 – Despite the availability of on-label products to treat diabetic retinopathy (DR), Genentech’s off-label option, Avastin, is the predominant first-line treatment. […]
US Ophthalmologists Report Increasing Trial of Roche/Genentech’s Vabysmo in Diabetic Macular Edema, Though Regeneron’s Eylea Maintains Its Strong Positioning, According to Spherix Global Insights
Coherus’ new ranibizumab biosimilar, Cimerli, and the anticipated 8mg aflibercept formulation are predicted to further shake up the DME landscape in 2023 EXTON, Pa., October 12, 2022 / PRNewswire / – Now on the market for over nine months, Roche/Genentech’s Vabysmo (faricimab-svoa) has had success in expanding the breadth of users. However, depth of use […]
Geographic Atrophy — A Look Into Clinical Development
Throughout my career in the ophthalmology field, I have come face to face with patients suffering from geographic atrophy (GA) and have witnessed firsthand the devastating impact it can have among those patients. I’ve grown passionate about educating others about the potential signs, symptoms, and consequences of GA, as well as the major risk factors […]
Economic Burden Forces Shift in Specialty Physicians’ Treatment Decisions and Relationship with Pharma
Over the past year, countries across the globe have reported multi-decade highs in inflation, with the United States recording its highest inflation rate in 40 years.1 The unprecedented rise in inflation is causing financial and economic strain on many households and businesses, resulting in a behavioral shift in consumers across the country. The U.S Bureau of […]
Economic Burden Forces Shift in Specialty Physicians’ Treatment Decisions and Relationship with Pharma, According to New Spherix Report
The inflationary economy and lasting effects of COVID-19 have caused staff and product shortages, a rise in labor costs, and increased patient sensitivity to medication costs EXTON, Pa., September 12, 2022 /PRNewswire/ — Over the past year, many countries have reported multi-decade highs in inflation, with the United States recording its highest inflation rate in […]
All Eyes on High-Dose Eylea as Roche’s New Vabysmo Makes Moderate Impact in Blockbuster Eye Disease Market
Roche’s Vabysmo is making inroads into the wet AMD eye disease market, but Regeneron’s behemoth Eylea is holding its own, and a new, higher dose version may further entrench Eylea. That’s according to the latest survey of 110 ophthalmologists from healthcare research consultants at Spherix. While ophthalmologists initially thought most Vabysmo uptake to be at the expense of […]
